License and Asset Purchase Agreements - Additional Information - Menarini License Agreement (Detail) - USD ($)	48 Months Ended
	Dec. 31, 2025	Apr. 30, 2023	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	May 23, 2018
Menarini License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial transaction			$ 75,000
License Agreement Terms [Member] | Menarini License Agreement [Member] | Global development of the Product | Future [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Documented Expenses	25.00%
Maximum Documented Expenses	$ 15,000,000
License Agreement Terms [Member] | Antengene Therapeutics [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial transaction				$ 11,700,000
Up-front Payment Arrangement [Member] | License Agreement Terms [Member] | Menarini License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial transaction		$ 3,500,000	75,000,000
Up-front Payment Arrangement [Member] | License Agreement Terms [Member] | Menarini License Agreement [Member] | Transaction Price at Contract Inception [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial transaction			$ 75,000,000
Up-front Payment Arrangement [Member] | License Agreement Terms [Member] | Antengene Therapeutics [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial transaction					$ 11,700,000	$ 11,700,000